Table 1 Baseline characteristics of the patients
Characteristics | Values (%) |
|---|---|
Median age (range), years | 69 (46–79) |
Sex, n (%) | |
Male | 21 (84.0) |
Female | 4 (16.0) |
Eastern Cooperative Oncology Group performance status, n (%) | |
0 | 23 (92.0) |
1 | 2 (8.0) |
Smoking, n (%) | |
Yes | 6 (24.0) |
No | 19 (76.0) |
Treatment regimens, n (%) | |
RC48 + Toripalimab | 13 (52.0) |
RC48 + Tislelizumab | 9 (36.0) |
RC48 + Pembrolizumab | 3 (12.0) |
Treatment cycles (range) | 5 (4–7) |
T stage, n (%) | |
T2 | 18 (72.0) |
T3 | 5 (20.0) |
T4 | 2 (8.0) |
N stage, n (%) | |
N0 | 18 (72.0) |
N1 | 5 (20.0) |
N2 | 2 (8.0) |
Baseline Pathological Typea, n (%) | |
Conventional UC | 16 (64.0) |
UC with squamous differentiation | 4 (16.0) |
Sarcomatoid UC | 5 (20.0) |
HER2 status, n (%) | |
IHC 0 | 1 (4.0) |
IHC 1+ | 1 (4.0) |
IHC 2+ | 10 (40.0) |
IHC 3+ | 13 (52.0) |
